Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00185965
Status:
COMPLETED
Last Update Posted:
2014-08-01
First Post:
2005-09-12
Brief Title:
CPG 7909 Local Radiotherapy in Recurrent Low-Grade Lymphomas
Sponsor:
Ronald Levy
Organization:
Stanford University
Study Overview
Official Title:
Le23 CPG A Phase 1-2 Study of Intratumoral Injection of CPG 7909 A TLR 9 Agonist Combined With Local Radiation in Recurrent Low-Grade Lymphomas
Status:
COMPLETED
Status Verified Date:
2014-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Brief summary TBD
Detailed Description:
This is a single institution phase 1-2 trial to evaluate the safety feasibility and efficacy of CpG injections 4 intratumoral injections followed by 6 peri-tumoral injections combined with local irradiation in patients with recurrent low-grade lymphomas
Patients will receive low-dose radiotherapy to a single tumor site on days 1 and 2 2 Gy each day CpG injections will be administered into the same tumor site within the 24 hours before and the 24 hours after the radiation and on days 8 and 15 Weekly doses of CpG will be then administered subcutaneously in the region of previous injections for 6 additional doses
Patients will receive low-dose radiotherapy to a single tumor site on days 1 and 2 2 Gy each day CpG injections will be administered into the same tumor site within the 24 hours before and the 24 hours after the radiation and on days 8 and 15 Weekly doses of CpG will be then administered subcutaneously in the region of previous injections for 6 additional doses
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| LYMNHL0014 | OTHER | OnCore | None |
| 80057 | OTHER | None | None |